Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 21Neoplasms 16Neuroblastoma 14Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Fallopian Tube Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lung Neoplasms 10Recurrence 8Leukemia 8Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 6Neoplasm Metastasis 6Lymphoma 6Sarcoma, Ewing 5Endometrial Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Sarcoma 4Lymphoma, Follicular 4Glioma 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Blast Crisis 4Rhabdomyosarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Meningeal Carcinomatosis 3Medulloblastoma 3

Interventions

LY3295668 erbumine 3Topotecan 1TAS-119 1Paclitaxel 1Midazolam 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Epilepsy × Topotecan × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡